Chronic Bilirubin Encephalopathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CBE MCID: CHR682 MIFTS: 42	Chronic Bilirubin Encephalopathy (CBE) Categories: Metabolic diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Chronic Bilirubin Encephalopathy

MalaCards integrated aliases for Chronic Bilirubin Encephalopathy:

Name: Chronic Bilirubin Encephalopathy ⁵⁸ ⁷⁵

Bilirubin-Induced Neurological Dysfunction ⁵⁸

Kernicterus Spectrum Disorder ⁵⁸

Bind ⁵⁸

Cbe ⁵⁸

Ksd ⁵⁸

Characteristics:

Prevelance:

1-9/100000 (Canada, Denmark, United States) ⁵⁸

Age Of Onset:

Infancy,Neonatal ⁵⁸

Classifications:

MalaCards categories:
Global: Metabolic diseases Rare diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare neurological diseases

Inborn errors of metabolism

Sources

Summaries for Chronic Bilirubin Encephalopathy

Orphanet: ⁵⁸ A rare neurologic disease characterized by the chronic consequences of bilirubin toxicity in the globus pallidus, sub-thalamic nuclei, and other brain regions, after exposure to high levels of unconjugated bilirubin in the neonatal period. Symptoms begin after the acute phase of bilirubin encephalopathy in the first year of life, evolve slowly over several years, and include mild to severe extrapyramidal disturbances (especially dystonia and athetosis), auditory neuropathy spectrum disorder, and oculomotor and dental abnormalities.

MalaCards based summary: Chronic Bilirubin Encephalopathy, also known as bilirubin-induced neurological dysfunction, is related to von willebrand disease, type 2 and cold agglutinin disease. The drugs Apomorphine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include globus pallidus, brain and smooth muscle, and related phenotypes are prolonged neonatal jaundice and hepatic encephalopathy

Wikipedia: ⁷⁵ Kernicterus is a bilirubin-induced brain dysfunction. The term was coined in 1904 by Christian Georg... more...

Sources

Related Diseases for Chronic Bilirubin Encephalopathy

Diseases in the Acute Bilirubin Encephalopathy family:

Chronic Bilirubin Encephalopathy

Diseases related to Chronic Bilirubin Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 877)

#	Related Disease	Score
1	von willebrand disease, type 2	11.1
2	cold agglutinin disease	11.1
3	retinoblastoma	11.0
4	myasthenia gravis	11.0
5	neuromyelitis optica	10.9
6	episodic ataxia	10.9
7	factor v leiden thrombophilia	10.9
8	helix syndrome	10.5
9	rapidly involuting congenital hemangioma	10.5
10	amyloidosis	10.5
11	human immunodeficiency virus type 1	10.5
12	major depressive disorder	10.4
13	kernicterus	10.4
14	encephalopathy	10.4
15	immune deficiency disease	10.4
16	hypolipoproteinemia	10.4
17	severe acute respiratory syndrome	10.4
18	herpes simplex	10.4
19	systemic lupus erythematosus	10.4
20	bilirubin metabolic disorder	10.4
21	lupus erythematosus	10.3
22	primary agammaglobulinemia	10.3
23	influenza	10.3
24	alzheimer disease, familial, 1	10.3
25	malaria	10.3
26	viral infectious disease	10.3
27	autoimmune disease	10.2
28	hepatitis c virus	10.2
29	iron metabolism disease	10.2
30	fetal anticonvulsant syndrome	10.2
31	amyotrophic lateral sclerosis 1	10.2
32	dengue disease	10.2
33	plasmodium falciparum malaria	10.2
34	leukemia	10.2
35	neuroblastoma	10.2
36	dengue virus	10.2
37	breast cancer	10.2
38	covid-19	10.2
39	cholera	10.2
40	hepatitis	10.2
41	lateral sclerosis	10.2
42	cytokine deficiency	10.2
43	henoch-schoenlein purpura	10.2
44	hepatitis c	10.2
45	turner syndrome	10.2
46	down syndrome	10.2
47	t-cell acute lymphoblastic leukemia	10.2
48	myeloid leukemia	10.2
49	ataxia with vitamin e deficiency	10.1
50	aspergillosis	10.1

Graphical network of the top 20 diseases related to Chronic Bilirubin Encephalopathy:

Sources

Symptoms & Phenotypes for Chronic Bilirubin Encephalopathy

Human phenotypes related to Chronic Bilirubin Encephalopathy:

⁵⁸ ³⁰ (show all 21)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	prolonged neonatal jaundice ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0006579
2	hepatic encephalopathy ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002480
3	neonatal hyperbilirubinemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003265
4	abnormal auditory evoked potentials ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0006958
5	intellectual disability ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001249
6	seizure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001250
7	sensorineural hearing impairment ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000407
8	hypertonia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001276
9	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
10	hemolytic anemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001878
11	cerebral palsy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100021
12	hypoalbuminemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003073
13	feeding difficulties ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0011968
14	central apnea ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002871
15	abnormal thalamic mri signal intensity ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012696
16	kernicterus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001343
17	conjunctival icterus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0032106
18	hypernatremia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003228
19	neonatal sepsis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0040187
20	visual gaze preference ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0025518
21	abnormal conjunctiva morphology ⁵⁸		Frequent (79-30%)

Sources

Drugs & Therapeutics for Chronic Bilirubin Encephalopathy

Drugs for Chronic Bilirubin Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Apomorphine

Approved, Investigational

Phase 4

41372-20-7, 58-00-4

6005

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Broncho-Vaxom

Phase 4

Adjuvants, Immunologic

Phase 4

Immunologic Factors

Phase 4

Neurotransmitter Agents

Phase 4

Dopamine agonists

Phase 4

Dopamine Agents

Phase 4

Emetics

Phase 4

Gastrointestinal Agents

Phase 4

Urinastatin

Phase 4

HIV Protease Inhibitors

Phase 4

Trypsin Inhibitors

Phase 4

Serine Proteinase Inhibitors

Phase 4

Pharmaceutical Solutions

Phase 4

protease inhibitors

Phase 4

Serine

Investigational, Nutraceutical

Phase 4

56-45-1

5951

Rimonabant

Approved, Investigational

Phase 3

168273-06-1, 158681-13-1

104850

Epoprostenol

Approved

Phase 3

61849-14-7, 35121-78-9

5282411

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 3

139755-83-2, 171599-83-0

5212 135398744

Iron

Approved

Phase 3

7439-89-6

29936

Rituximab

Approved

Phase 3

174722-31-7

Nitric Oxide

Approved

Phase 3

10102-43-9

145068

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Arginine

Approved, Investigational, Nutraceutical

Phase 3

74-79-3

6322

Tezosentan

Investigational

Phase 3

180384-57-0

Apaziquone

Investigational

Phase 3

114560-48-4

5813717

Anti-Obesity Agents

Phase 3

Phosphodiesterase Inhibitors

Phase 3

Phosphodiesterase 5 Inhibitors

Phase 3

Vasodilator Agents

Phase 3

Citrate

Phase 3

Blood Substitutes

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Antirheumatic Agents

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Citalopram

Approved

Phase 2

59729-32-7, 59729-33-8

2771

Leuprolide

Approved, Investigational

Phase 2

53714-56-0

657181

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Dexetimide

Withdrawn

Phase 2

21888-98-2

30843

Psychotropic Drugs

Phase 2

Antidepressive Agents

Phase 2

Serotonin Uptake Inhibitors

Phase 2

Hormones

Phase 2

Hormone Antagonists

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Abiraterone Acetate

Phase 2

154229-18-2

9821849

Interventional clinical trials:

(show all 27)

#	Name	Status	NCT ID	Phase	Drugs
1	International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity	Completed	NCT03301155	Phase 4	Anaferon for children;Placebo
2	Prospective, Pivotal Unicentre, Randomized Double-bind, Placebo-controlled Study, to Evaluate Efficacy and Safety of Bacterial Lysates (Pulmonarom) in the Prevention of Respiratory Tract Infections	Completed	NCT00599417	Phase 4	Bacterial Lysates;placebo
3	Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease	Active, not recruiting	NCT02940912	Phase 4	Apomorphine;Placebo
4	Multicenter, Double-bind, Randomised, Placebo Controlled Study of Ulinastatin in Severe Acute Pancreatitis	Suspended	NCT01132521	Phase 4	ulinastatin;placebo
5	A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving	Completed	NCT00481975	Phase 3	rimonabant (SR141716)
6	A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 With or Without Hypocaloric Diet in Obese Patients	Completed	NCT00481923	Phase 3	rimonabant (SR141716)
7	A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.	Completed	NCT00159861	Phase 3	Sildenafil citrate
8	Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period.	Completed	NCT01154491	Phase 3	Ferric carboxymaltose;Erythropoietin;Placebo
9	Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial	Completed	NCT01181154	Phase 3	rituximab (Mabthera®);Placebo
10	L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial	Terminated	NCT00549575	Phase 3	L ARG;Placebo
11	A Phase 3 International, Double-Bind Trial Evaluating Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)	Terminated	NCT01469221	Phase 3	Apaziquone;Placebo
12	An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer	Completed	NCT02283320	Phase 2	BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
13	A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder	Completed	NCT01020799	Phase 2	AZD7268;Escitalopram;Placebo capsules;Placebo tablets
14	An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer	Completed	NCT01812746	Phase 2	BIND-014
15	An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer	Completed	NCT01792479	Phase 2	BIND-014
16	An Evolutionary Double Bind Phase II Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Eligible for Prostatectomy	Not yet recruiting	NCT05574712	Phase 2	Neoadjuvant treatment
17	A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck	Terminated	NCT02479178	Phase 2	BIND-014 (docetaxel nanoparticles for injectable suspension)
18	A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward	Completed	NCT00605241	Phase 1	GSK598809
19	A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer	Completed	NCT01300533	Phase 1	BIND-014
20	Validation of Bilirubin Binding Capacity (BBC) Using AVIV Device	Completed	NCT02612207
21	CAN-BIND (Canadian Biomarker Integration Network for Depression): Long-Term Follow Up Study	Completed	NCT02998762
22	A Prospective, Multicenter, Randomized and Single Bind Trial. Influence of Laryngoscope Blade Material on Postoperative PHARYNGEAL AND LARYNGEAL Morbidity Following Scheduled OroTracheal Intubation	Completed	NCT01118533
23	The Ties That Bind: Evaluation of a Patient-worn Pulse Oximeter Compared to Traditional Pulse Oximetry on Loss of Signal Integrity in Pediatric Patients	Completed	NCT03187665
24	A Collaborative Investigation of Predictors of Relapse in Major Depressive Disorder: CAN-BIND-1 Extension Study	Completed	NCT02934334
25	Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5 and WP6) Part 2: a Neurobehavioural and MRI Study	Recruiting	NCT04668716
26	Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5) Part 1: a Multicentre Online Phenotyping and Neurobehavioural Data Collection Study	Recruiting	NCT04583917
27	Effect of Glutaraldehyde-based Desensitizer in the Control of Tooth Sensitivity and Tooth Color Post- Whitening : Clinical, Randomized,Double Bind and Split Mouth Study	Recruiting	NCT05309967

Search NIH Clinical Center for Chronic Bilirubin Encephalopathy

Sources

Genetic Tests for Chronic Bilirubin Encephalopathy

Sources

Anatomical Context for Chronic Bilirubin Encephalopathy

Organs/tissues related to Chronic Bilirubin Encephalopathy:

MalaCards : Globus Pallidus, Brain, Smooth Muscle, Prostate, Endothelial, T Cells, Lung

Sources

Publications for Chronic Bilirubin Encephalopathy

Articles related to Chronic Bilirubin Encephalopathy:

(show top 50) (show all 30069)

#	Title	Authors	PMID	Year
1	KAP is the neuronal organelle adaptor for Kinesin-2 KIF3AB and KIF3AC. ⁶²	Garbouchian A...Bentley M	36200888	2022
2	Searching for drug leads targeted to the hydrophobic cleft of dengue virus capsid protein. ⁶²	Ortlieb LO...Almeida FCL	34894959	2022
3	Extraintestinal pathogenic Escherichia coli utilizes the surface-expressed elongation factor Tu to bind and acquire iron from holo-transferrin. ⁶²	Sun Y...Dai J	35443872	2022
4	The cytosolic iron-sulphur cluster assembly mechanism in grapevine is one target of a virulent Crinkler effector from Plasmopara viticola. ⁶²	Xiang G...Xu Y	36071584	2022
5	Natural LILRB1 D1-D2 variants show frequency differences in populations and bind to HLA class I with various avidities. ⁶²	Liu F...Guethlein LA	35562487	2022
6	Divergent polo boxes in KKT2 bind KKT1 to initiate the kinetochore assembly cascade in Trypanosoma brucei. ⁶²	Ishii M...Akiyoshi B	36129769	2022
7	GATA4 and estrogen receptor alpha bind at SNPs rs9921222 and rs10794639 to regulate AXIN1 expression in osteoblasts. ⁶²	Suthon S...Krum SA	35678873	2022
8	Cryo-EM structure shows how two IGF1 hormones bind to the human IGF1R receptor. ⁶²	Wu C...Zhang X	36332473	2022
9	MoS2 nanosheets effectively bind to the receptor binding domain of the SARS-CoV-2 spike protein and destabilize the spike-human ACE2 receptor interactions. ⁶²	Bisht D...Jaiswal A	36382499	2022
10	Cisplatin toxicity is mediated by direct binding to TLR4 through a mechanism that is distinct from metal allergens. ⁶²	Domingo IK...Bhavsar AP	36460345	2022
11	Recognition of cyclic dinucleotides and folates by human SLC19A1. ⁶²	Zhang Q...Gao P	36265513	2022
12	Practical Guidance for Consensus Scoring and Force Field Selection in Protein-Ligand Binding Free Energy Simulations. ⁶²	Zhang H...Im W	36399655	2022
13	The transcription factor E2A can bind to and cleave single-stranded immunoglobulin heavy chain locus DNA. ⁶²	Grundstrom C...Grundstrom T	36434987	2022
14	Human 14-3-3 Proteins Site-selectively Bind the Mutational Hotspot Region of SARS-CoV-2 Nucleoprotein Modulating its Phosphoregulation. ⁶²	Tugaeva KV...Sluchanko NN	36427566	2022
15	Replication Protein A Utilizes Differential Engagement of Its DNA-Binding Domains to Bind Biologically Relevant ssDNAs in Diverse Binding Modes. ⁶²	Wieser TA...Wuttke DS	36278947	2022
16	The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX. ⁶²	Fenton M...Daughdrill G	36181774	2022
17	Characterization of antibody clones that bind exclusively to insoluble fibrin. ⁶²	Fuchigami H...Matsumura Y	36239546	2022
18	Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune. ⁶²	Timofeeva AM...Nevinsky GA	36430159	2022
19	Flavin Adenine Dinucleotide (FAD) and Pyridoxal 5'-Phosphate (PLP) Bind to Sox9 and Alter the Expression of Key Pancreatic Progenitor Transcription Factors. ⁶²	Islam Z...Kolatkar PR	36430529	2022
20	Low-Molecular Weight Small Molecules Can Potently Bind RNA and Affect Oncogenic Pathways in Cells. ⁶²	Suresh BM...Disney MD	36322830	2022
21	1,4-Dideoxy-1,4-imino-D- and L-lyxitol-based inhibitors bind to Golgi α-mannosidase II in different protonation forms. ⁶²	Kona J...Polakova M	36322142	2022
22	Synthesis and properties of oligodiaminogalactoses that bind to A-type oligonucleotide duplexes. ⁶²	Shiraishi T...Wada T	36222332	2022
23	Mcm2 promotes stem cell differentiation via its ability to bind H3-H4. ⁶²	Xu X...Zhang Z	36354740	2022
24	Bacterial-Type Long-Chain Polyphosphates Bind Human Proteins in the Phosphatidylinositol Signaling Pathway. ⁶²	Krenzlin V...Bosmann M	35909349	2022
25	Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARγ. ⁶²	Almahmoud S...Zhong HA	36358965	2022
26	ZER1 Contributes to the Carcinogenic Activity of High-Risk HPV E7 Proteins. ⁶²	Nouel J...White EA	36346242	2022
27	High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire. ⁶²	Kucharska I...Julien JP	36441829	2022
28	Discovery of small molecules that target a tertiary-structured RNA. ⁶²	Menichelli E...Rogers J	36413497	2022
29	Better assessment of neonatal jaundice at home (BEAT Jaundice @home): protocol for a prospective, multicentre diagnostic study. ⁶²	Westenberg LEH...Been JV	36396315	2022
30	Glycan-mediated interactions between bacteria, rotavirus and the host cells provide an additional mechanism of antiviral defence. ⁶²	Raev SA...Vlasova AN	36239669	2022
31	The Ties That Bind: Glial Transplantation in White Matter Ischemia and Vascular Dementia. ⁶²	Carmichael ST...Llorente IL	36357662	2022
32	Host and viral proteins involved in SARS-CoV-2 infection differentially bind heme. ⁶²	Hopp MT...Imhof D	36161737	2022
33	Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage. ⁶²	Li Q...Holmdahl R	36419093	2022
34	Polyol and sugar osmolytes stabilize the molten globule state of α-lactalbumin and inhibit amyloid fibril formation. ⁶²	Rahamtullah...Mishra R	36096464	2022
35	Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study. ⁶²	Kim HK...Kloiber S	35793696	2022
36	IgG fractions from patients with antiphospholipid syndrome and systemic lupus erythematosus bind to platelets, but do not affect collagen-induced platelet activation. ⁶²	Ho YC...Adams MJ	35394397	2022
37	The emerging importance of immunophilins in fibrosis development. ⁶²	Alqudah A...McClements L	36302992	2022
38	The Sialyl Lewis X Glycan Receptor Facilitates Infection of Subtype H7 Avian Influenza A Viruses. ⁶²	Guan M...Wan XF	36125302	2022
39	Pathogenic Neisseria Bind the Complement Protein CFHR5 via Outer Membrane Porins. ⁶²	Yee WX...Lavender H	36194022	2022
40	Viral infections and drug hypersensitivity. ⁶²	Pichler WJ...Bruggen MC	36264263	2022
41	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. ⁶²	Copertino DC...Nixon DF	33734021	2022
42	Insight into the C-terminal SH3 domain mediated binding of Drosophila Drk to Sos and Dos. ⁶²	Sayeesh PM...Ito Y	35952612	2022
43	Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk. ⁶²	Mangangcha IR...Ali S	33769184	2022
44	Hold your horses: The receptor-binding domains of SARS-CoV-2, SARS-CoV, and hCoV-NL63 bind equine ACE2. ⁶²	Nawrath P...Wrobel AG	36206735	2022
45	Barley metallothionein isoforms, MT2b2 and MT4, differentially respond to photohormones in barley aleurone layer and their recombinant forms show different affinity for binding to zinc and cadmium. ⁶²	Pourjalali Z...Golkar P	36309886	2022
46	Topological zero-dimensional defect and flux states in three-dimensional insulators. ⁶²	Schindler F...Wieder BJ	36184669	2022
47	Isolation of a Peptide That Binds to Pseudomonas aeruginosa Lytic Bacteriophage. ⁶²	Chan SK...Steinmetz NF	36312416	2022
48	The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis. ⁶²	Wang H...Fogelman AM	35979993	2022
49	Nucleophilic Thiol Proteins Bind Covalently to Abasic Sites in DNA. ⁶²	Ghodke PP...Guengerich FP	35482010	2022
50	Anamnestic broadly reactive antibodies induced by H7N9 virus more efficiently bind to seasonal H3N2 strains. ⁶²	Chen Y...Huang J	36197079	2022